Stock Ratings / Health Care / JAGX / dividends

RADX (61) NCEL (39) CTXR (49) NEUP (32) ⌘ Pro Terminal →

Jaguar Health Inc. (JAGX) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.04 -2.86% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Jaguar Health Inc. (JAGX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $15.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JAGX)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring JAGX)

✓Walkthrough of JAGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JAGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.05%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.00H $2.04L $1.60C $2.04VOL 371.2K

RES: $39.31SUP: $-7.12SMA50: $6.46SMA200: $120.1

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JAGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JAGX Butterfly Map → + Track JAGX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -1.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JAGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JAGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JAGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JAGX)

Health Care Rank #934 of 1016 ⚔️ RADX vs JAGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JAGX vs. RADX, NCEL, CTXR, NEUP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Jaguar Health Inc. (JAGX) ranks #934 by composite RQD confidence (31/100, grade E) and #854 by equity capitalization ($15.9M). Within this direct 5-issuer industry benchmark cohort, JAGX leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with JAGX at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JAGX ACTIVE Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	Benchmark Subject
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-jagx →
NCEL NewcelX Ltd.	D-	39/100	—	—	-35.0%	-0.30%	$15.5M	/ncel-vs-jagx →
CTXR Citius Pharmaceuticals Inc.	D	49/100	—	—	-35.0%	+4.07%	$15.5M	/ctxr-vs-jagx →
NEUP Neuphoria Therapeutics Inc.	E	32/100	—	—	-11.8%	-8.93%	$16.6M	/neup-vs-jagx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001585608

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Jaguar Health Inc. (JAGX) reported GAAP revenue of $11.5M (-1.5% vs. FY2024 revenue of $11.7M , and +17.9% cumulative change since FY2023) , GAAP net income of -$54.0K, operating cash flow of -$23.7M, and free cash flow of -$23.7M (+19.4% YoY). On the balance sheet, JAGX closed FY2025 with $38.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$11.5M	-$54.0K	-$23.7M	-$23.7M	$38.3M	—
FY2024 (FY)	2024-12-31	$11.7M	-$39.3K	-$29.4M	-$29.4M	$53.4M	—
FY2023 (FY)	2023-12-31	$9.8M	-$41.9K	-$33.2M	-$33.2M	—	—

3. JAGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JAGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Jaguar Health Inc. (NASDAQ: JAGX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.04 (-2.86% 1D, market cap $15.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, JAGX ranks #934 in composite RQD confidence.

How does JAGX compare to RADX and NCEL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JAGX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 67.2%, and ROIC of -35.0%. By comparison, RADX (Radiopharm Theranostics Limited) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $16.1M) and NCEL (NewcelX Ltd.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $15.5M). Among the 5-stock peer group, JAGX leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JAGX?

Per JAGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001585608), Jaguar Health Inc. generated $11.5M in revenue (-1.5% YoY), -$54.0K in net income, and -$23.7M in free cash flow against $38.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JAGX trading relative to its 50-day, 200-day, and 52-week technical levels?

JAGX last traded at $2.04 (-2.86% on volume of 291,768 shares), positioning the stock -68.42% below its 50-day simple moving average ($6.46) and -98.30% below its 200-day simple moving average ($120.10). Across its 52-week range of $1.60 to $1,102.50, JAGX sits at the 0.0% percentile with a 14-day RSI of 39.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.78 to $2.30).

JAGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does JAGX pay a dividend and is it safe?

Jaguar Health Inc. (JAGX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: JAGX RQD Cockpit JAGX 12M Forecast JAGX Earnings & Move JAGX Dividends & DRIP JAGX Insiders & 13F JAGX Whale Options JAGX Profit Sankey JAGX News & Why